Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

This announcement is for information purposes only and does not constitute an invitation or offer to acquire, purchase or subscribe for any securities nor is it calculated to invite any such offer or invitation. In particular, this announcement does not constitute and is not an offer to sell or an invitation or a solicitation of any offer to buy or subscribe for any securities in Hong Kong, the United States of America or elsewhere. Securities may not be offered or sold in the United States of America absent registration or an exemption from registration under the United States Securities Act of 1933, as amended (the ''U.S. Securities Act''). The securities described herein have not been and will not be registered under the U.S. Securities Act. There will be no public offering of securities in the United States of America, the State of Israel or any jurisdiction other than Hong Kong.

Not for release, publication or distribution, in whole or in part, directly or indirectly, in, into or from the United States of America or any jurisdiction where to do so would constitute a violation of the relevant laws or regulations of such jurisdiction.

上 海 復 星 醫 藥 （ 集 團 ） 股 份 有 限 公 司

Shanghai Fosun Pharmaceutical (Group) Co., Ltd.*

(a joint stock limited company incorporated in the People's Republic of China with limited liability)

(Stock Code: 02196)

JOINT ANNOUNCEMENT

THE PROPOSED SPIN-OFF AND SEPARATE LISTING OF SISRAM MEDICAL LTD ON THE MAIN BOARD OF THE STOCK EXCHANGE OF HONG KONG LIMITED

LISTING OF SISRAM MEDICAL LTD AND COMMENCEMENT OF DEALINGS IN THE SISRAM SHARES

The boards of directors of Fosun Pharma and Fosun International are pleased to announce that following the completion of the Global Offering, listing of Sisram on the Main Board of the Hong Kong Stock Exchange took place on 19 September 2017 and dealings in the Sisram Shares on the Main Board of the Hong Kong Stock Exchange commenced at 9: 00 a.m. on 19 September 2017.

  1. Introduction

    Fosun Pharma refers to its announcements dated 29 June 2016, 31 August 2016, 6 June 2017, 20

    August 2017, 30 August 2017, 5 September 2017 and 12 September 2017 (the ''Fosun Pharma Announcements'') and the circular to its shareholders dated 15 July 2016 relating to the Proposed Spin-off and Listing. The Proposed Spin-off and Listing were approved by Fosun Pharma's shareholders at the 2016 Second Extraordinary General Meeting held on 31 August 2016.

    Fosun International refers to its announcements dated 6 June 2017, 17 August 2017, 20 August 2017, 30 August 2017, 5 September 2017 and 12 September 2017 (the ''Fosun International Announcements'') relating to the Proposed Spin-off and Listing.

    Unless the context otherwise requires, terms defined in the Fosun Pharma Announcements and the Fosun International Announcements shall have the same meanings as those used in this announcement.

  2. Listing of Sisram and Commencement of dealings in the Sisram Shares

The Hong Kong Stock Exchange has granted the listing of, and permission to deal in, the Sisram Shares on the Main Board of the Hong Kong Stock Exchange.

Following the completion of the Global Offering, (i) listing of Sisram on the Main Board of the Hong Kong Stock Exchange took place on 19 September 2017 and (ii) dealings in the Sisram Shares on the Main Board of the Hong Kong Stock Exchange commenced at 9: 00 a.m. on 19 September 2017. The Sisram Shares are traded in board lots of 400 Sisram Shares each and the stock code is 1696.

The spin-off and separate listing of Sisram from Fosun Pharma and Fosun International promotes the achievement of transcending developments by Sisram on a higher platform and the enhancement of the overall value of Fosun Pharma and Fosun International.

By order of the board

Shanghai Fosun Pharmaceutical (Group) Co., Ltd.* Chen Qiyu

Chairman

By order of the board

Fosun International Limited Guo Guangchang

Chairman

19 September 2017

As at the date of this announcement, the executive directors of Fosun Pharma are Mr. Chen Qiyu, Mr. Yao Fang and Mr. Wu Yifang; the non-executive directors are Mr. Guo Guangchang, Mr. Wang Qunbin, Ms. Kang Lan and Mr. Wang Can; and the independent non-executive directors are Mr. Cao Huimin, Mr. Jiang Xian, Dr. Wong Tin Yau Kelvin and Mr. Wai Shiu Kwan Danny.

As at the date of this announcement, the executive directors of Fosun International are Mr. Guo Guangchang, Mr. Wang Qunbin, Mr. Chen Qiyu, Mr. Xu Xiaoliang, Mr. Qin Xuetang, Mr. Wang Can, Ms. Kang Lan and Mr. Gong Ping; and the independent non-executive directors are Mr. Zhang Shengman, Mr. Zhang Huaqiao, Mr. David T. Zhang, Mr. Yang Chao and Dr. Lee Kai-Fu.

* For identification purposes only

Fosun International Limited published this content on 19 September 2017 and is solely responsible for the information contained herein.
Distributed by Public, unedited and unaltered, on 19 September 2017 09:09:03 UTC.

Original documenthttp://media.corporate-ir.net/media_files/IROL/19/194273/2017/E02196 0919_1305.pdf

Public permalinkhttp://www.publicnow.com/view/9117EF96E06315248D63CC4AA926B6EDE1C867A0